Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n° 344

The American Society of Nephrology Kidney Week 2019 Annual Meeting

Posted by fidest press agency su venerdì, 8 novembre 2019

Goldfinch Bio, a U.S.-based, clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced it will present one oral and two poster presentations at the American Society of Nephrology (ASN) Kidney Week 2019 Annual Meeting, taking place November 5-10, 2019, in Washington, D.C.The oral presentation will address the ways in which Goldfinch Bio’s platform generates induced pluripotent stem cell (iPSC)-derived human podocytes and kidney organoids to enable target validation and preclinical assessment of prospective therapies for kidney disease. The poster presentations will include data on how GFB-887, a sub-type selective, small molecule transient receptor potential canonical 5 (TRPC5) ion channel inhibitor, was effective in reducing proteinuria in animal models of focal segmental glomerulosclerosis (FSGS) and other kidney diseases, as well as data on how Goldfinch Bio’s proprietary Kidney Genome AtlasTM can be leveraged to unravel molecular mechanisms of kidney diseases.

Rispondi

Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:

Logo di WordPress.com

Stai commentando usando il tuo account WordPress.com. Chiudi sessione /  Modifica )

Google photo

Stai commentando usando il tuo account Google. Chiudi sessione /  Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione /  Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione /  Modifica )

Connessione a %s...

 
%d blogger hanno fatto clic su Mi Piace per questo: